Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma

Abstract Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major ro...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Corey Smith, Margaret McGrath, Michelle A. Neller, Katherine K. Matthews, Pauline Crooks, Laetitia Le Texier, Benedict Panizza, Sandro Porceddu, Rajiv Khanna
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/2ff4c31e55df41fc9e1e70e5cbd4cff1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:2ff4c31e55df41fc9e1e70e5cbd4cff1
record_format	dspace
spelling	oai:doaj.org-article:2ff4c31e55df41fc9e1e70e5cbd4cff12021-12-02T16:30:41ZComplete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma10.1038/s41698-021-00162-72397-768Xhttps://doaj.org/article/2ff4c31e55df41fc9e1e70e5cbd4cff12021-03-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00162-7https://doaj.org/toc/2397-768XAbstract Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients.Corey SmithMargaret McGrathMichelle A. NellerKatherine K. MatthewsPauline CrooksLaetitia Le TexierBenedict PanizzaSandro PorcedduRajiv KhannaNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Corey Smith Margaret McGrath Michelle A. Neller Katherine K. Matthews Pauline Crooks Laetitia Le Texier Benedict Panizza Sandro Porceddu Rajiv Khanna Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
description	Abstract Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients.
format	article
author	Corey Smith Margaret McGrath Michelle A. Neller Katherine K. Matthews Pauline Crooks Laetitia Le Texier Benedict Panizza Sandro Porceddu Rajiv Khanna
author_facet	Corey Smith Margaret McGrath Michelle A. Neller Katherine K. Matthews Pauline Crooks Laetitia Le Texier Benedict Panizza Sandro Porceddu Rajiv Khanna
author_sort	Corey Smith
title	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
title_short	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
title_full	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
title_fullStr	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
title_full_unstemmed	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
title_sort	complete response to pd-1 blockade following ebv-specific t-cell therapy in metastatic nasopharyngeal carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2ff4c31e55df41fc9e1e70e5cbd4cff1
work_keys_str_mv	AT coreysmith completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT margaretmcgrath completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT michelleaneller completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT katherinekmatthews completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT paulinecrooks completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT laetitialetexier completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT benedictpanizza completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT sandroporceddu completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT rajivkhanna completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma
_version_	1718383919725805568

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma

Documents similaires